NCAM1 and metastatic melanoma: This is consistent with a previous report showing up-regulation of GPR160 in cancerous prostate duct cells, CD4+CD56+ hematodermic neoplasm, metastatic melanoma and nasopharyngeal carcinoma cells [13–16].